Article Text

Download PDFPDF
Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells
  1. M. E. Beiner*,
  2. H. Niv,
  3. R. Haklai,
  4. G. Elad-Sfadia,
  5. Y. Kloog and
  6. G. Ben-Baruch*
  1. * Department of Gynecologic Oncology, Sheba Medical Center, Tel-Hashomer, Israel
  2. Department of Neurobiochemistry, George S. Wise Faculty of Life Science, Tel-Aviv University, Tel-Aviv, Israel
  1. Address correspondence and reprint requests to: Mario E. Beiner, MD, Department of Gynecologic Oncology, Sheba Medical Center, 53621 Tel-Hashomer, Israel. Email: lmbeiner{at}


The objective of this article was to determine whether human ovarian carcinoma cells (OVCAR-3) express significant amounts of Ras oncogene and active Ras–guanosine triphosphate (GTP) and, if so, whether the Ras inhibitor farnesyl thiosalicylic acid (FTS) inhibits their growth and chemosensitizes them to cisplatin. We assayed Ras and Ras-GTP in OVCAR-3 cells before and after FTS treatment. The effect of FTS on OVCAR-3 cell growth was assessed in terms of cell number. Because the OVCAR-3 cell line was derived from a patient who was refractory to cisplatin, we examined whether FTS enables cisplatin to induce death of these cells. Significant amounts of Ras and active Ras-GTP were expressed by OVCAR-3 cells and were reduced by 40% by FTS. FTS inhibited OVCAR-3 cell growth in a dose-dependent manner. When combined with cisplatin, FTS reduced the number of OVCAR-3 cells by 80%, demonstrating synergism between FTS and cisplatin. FTS, at a concentration range that allows downregulation of Ras and Ras-GTP in OVCAR-3 cells, also chemosensitizes these cells and inhibits their growth. These results suggest that ovarian carcinomas might respond well to Ras inhibition, both alone and when combined with cisplatin. The combined treatment would allow the use of smaller doses of chemotherapy, resulting in decreased cytotoxicity.

  • cisplatin
  • OVCAR-3
  • Ras

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.